“…we hereby notify that the Goods & Service Tax Department, Maharashtra have concluded their Inspection/Search on 08th February, 2026,” according to a stock exchange filing.
Also Read: Indoco Remedies shares gain over 8.5% post USFDA approval for Lacosamide oral solution
The company stated that the inspection/search has no material impact on its financials, operations, or other activities.Third Quarter Results
Indoco Remedies Ltd. reported a wider net loss for the December quarter. The company posted a net loss of ₹29.8 crore for the quarter, compared with a loss of ₹26.4 crore in the corresponding period last year.
Revenue rose 8.5% year-on-year to ₹445.4 crore from ₹410.6 crore. Operating performance strengthened, with EBITDA coming in at ₹31.5 crore, nearly tripling from ₹12 crore a year ago. EBITDA margins expanded to 7.1% from 2.9% in the year-ago quarter.
Also Read: Indoco Remedies shares gain after Q2 net loss improves, revenue rises 12%
Shares of Indoco Remedies Ltd ended at ₹205.10, down by ₹8.65, or 4.05%, on the BSE.

